SEC Contract Filing

Filing Date: 2020-08-07

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>ex10_1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution
Version</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT </B>(this &quot;<B>Agreement</B>&quot;), dated as of August 4, 2020, by and among Generex Biotechnology Corporation,
a Delaware corporation, with headquarters located at 10102 USA Today Way, Miramar, Florida 33025 (the &quot;<B>Company</B>&quot;),
and the investors listed on the Schedule of Buyers attached hereto (individually, a &quot;<B>Buyer</B>&quot; and collectively,
the &quot;<B>Buyers</B>&quot;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS<FONT STYLE="font-weight: normal">:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.
The Company and each Buyer is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the &quot;<B>1933 Act</B>&quot;), and Rule 506(b) of Regulation
D (&quot;<B>Regulation D</B>&quot;) as promulgated by the United States Securities and Exchange Commission (the &quot;<B>SEC</B>&quot;)
under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.
Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i) that
aggregate number of shares of the Company's common stock, par value $0.001 per share (the &quot;<B>Common Stock</B>&quot;), set
forth opposite such Buyer's name in column (3) on the Schedule of Buyers (which aggregate amount for all Buyers together shall
be 5,102,040 shares of Common Stock and shall collectively be referred to herein as the &quot;<B>Common Shares</B>&quot;), (ii)
warrants, in substantially the form attached hereto as <U>Exhibit A</U> (the &quot;<B>Series A Warrants</B>&quot;), representing
the right to acquire that number of shares of Common Stock in accordance with its terms and conditions (as exercised, collectively,
the &quot;<B>Series A Warrant Shares</B>&quot;), (iii) warrants, in substantially the form attached hereto as <U>Exhibit B</U>
(the &quot;<B>Series B Warrants</B>&quot;), representing the right to acquire that number of shares of Common Stock in accordance
with its terms and conditions (as exercised, collectively, the &quot;<B>Series B Warrant Shares</B>&quot;), (iv) warrants, in
substantially the form attached hereto as <U>Exhibit C</U> (the &quot;<B>Series C Warrants</B>&quot;), representing the right
to acquire that number of shares of Common Stock in accordance with its terms and conditions (as exercised, collectively, the
&quot;<B>Series C Warrant Shares</B>&quot;) and (v) warrants, in substantially the form attached hereto as <U>Exhibit D</U> (the
&quot;<B>Series D Warrants</B>&quot; and, together with the Series A Warrants, Series B Warrants and Series C Warrants, the &quot;<B>Warrants</B>&quot;),
representing the right to acquire that number of shares of Common Stock in accordance with its terms and conditions (as exercised,
collectively, the &quot;<B>Series D Warrant Shares</B>&quot; and, together with the Series A Warrant Shares, Series B Warrant
Shares and Series C Warrant Shares, the &quot;<B>Warrant Shares</B>&quot;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
Contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration
Rights Agreement, in substantially the form attached hereto as <U>Exhibit E</U> (the &quot;<B>Registration Rights Agreement</B>&quot;),
pursuant to which the Company has agreed to provide certain registration rights with respect to the Registrable Securities (as
defined in the Registration Rights Agreement) under the 1933 Act and the rules and regulations promulgated thereunder, and applicable
state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times Ne